Aeglea BioTherapeutics Inc. (AGLE) Performance and Fundamentals Dashboard tells a completely different story

Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock jumped 0.13% on Tuesday to $0.15 against a previous-day closing price of $0.15. With 0.52 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.75 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1530 whereas the lowest price it dropped to was $0.1475. The 52-week range on AGLE shows that it touched its highest point at $1.64 and its lowest point at $0.14 during that stretch. It currently has a 1-year price target of $3.12. Beta for the stock currently stands at 1.74.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AGLE was up-trending over the past week, with a rise of 0.81%, but this was down by -7.85% over a month. Three-month performance dropped to -67.31% while six-month performance fell -87.59%. The stock lost -89.99% in the past year, while it has lost -66.61% so far this year. A look at the trailing 12-month EPS for AGLE yields -0.86 with Next year EPS estimates of -0.10. For the next quarter, that number is -0.12. This implies an EPS growth rate of 0.60% for this year and 78.00% for next year.

Float and Shares Shorts:

At present, 94.26 million AGLE shares are outstanding with a float of 60.28 million shares on hand for trading. On Apr 27, 2023, short shares totaled 0.43 million, which was 0.66% higher than short shares on Mar 30, 2023. In addition to Mr. Jeffrey M. Goldberg as the firm’s Pres, CEO & Director, Mr. Jonathan D. Alspaugh M.B.A. serves as its CFO & Principal Accounting Officer.

Institutional Ownership:

Through their ownership of 69.84% of AGLE’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.78% of AGLE, in contrast to 45.28% held by mutual funds. Shares owned by individuals account for 17.80%. As the largest shareholder in AGLE with 7.05% of the stake, Nantahala Capital Management LLC holds 4,611,302 shares worth 4,611,302. A second-largest stockholder of AGLE, Suvretta Capital Management LLC, holds 4,059,894 shares, controlling over 6.21% of the firm’s shares. Rock Springs Capital Management L is the third largest shareholder in AGLE, holding 3,413,906 shares or 5.22% stake. With a 2.18% stake in AGLE, the Pictet – Biotech is the largest stakeholder. A total of 1,425,961 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 1.96% of AGLE stock, is the second-largest Mutual Fund holder. It holds 1,282,021 shares valued at 0.22 million. FCP Medical – BioHealth holds 1.19% of the stake in AGLE, owning 775,223 shares worth 0.13 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, AGLE reported revenue of $625.00k and operating income of -$22.42M. The EBITDA in the recently reported quarter was -$22.05M and diluted EPS was -$0.27.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AGLE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AGLE analysts setting a high price target of $6.00 and a low target of $0.35, the average target price over the next 12 months is $2.84. Based on these targets, AGLE could surge 3900.0% to reach the target high and rise by 133.33% to reach the target low. Reaching the average price target will result in a growth of 1793.33% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded AGLE stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 2 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 118,200 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *